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We recently identified a novel vancomycin-resistant Enterococcus faecium (VREfm) clone
ST736 with reduced daptomycin susceptibility. The objectives of this study were to assess
the population dynamics of local VREfm strains and genetic alterations predisposing to dap-
tomycin resistance in VREfm ST736 strains. Multilocus sequence typing and single nucleo-
tide variant data were derived from whole-genome sequencing of 250 E. faecium isolates
from 1994–1995 (n = 43), 2009–2012 (n = 115) and 2013 (n = 92). A remarkable change
was noticed in the clonality and antimicrobial resistance profiles of E. faecium strains
between 1994–1995 and 2013. VREfm sequence type 17 (ST17), the prototype strain of
clade A1, was the dominant clone (76.7%) recognized in 1994–1995. By contrast, clone
ST736 accounted for 46.7% of VREfm isolates, followed by ST18 (26.1%) and ST412
(20.7%) in 2013. Bayesian evolutionary analysis suggested that clone ST736 emerged
between 1996 and 2009. Co-mutations (liaR.W73C and liaS.T120A) of the liaFSR system
were identified in all ST736 isolates (n = 111, 100%) examined. Thirty-eight (34.2%) ST736
isolates exhibited daptomycin-resistant phenotype, of which 13 isolates had mutations in
both the liaFSR and cardiolipin synthase (cls) genes and showed high level of resistance
with a daptomycin MIC50 of 32 μg/mL. The emergence of ST736 strains with mutations pre-
disposing to daptomycin resistance and subsequent clonal spread among inpatients contrib-
uted to the observed high occurrence of daptomycin resistance in VREfm at our institution.
The expanding geographic distribution of ST736 strains in other states and countries raises
concerns about its global dissemination.
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Introduction
Vancomycin-resistant Enterococcus faecium (VREfm) belonging to the epidemic hospital clade
A1, including strains of the clonal complex 17 (CC17) group, have emerged globally since the
1990’s and are now among the predominant group of enterococci causing nosocomial infec-
tions [1–3]. According to the US National Healthcare Safety Network (NHSN), enterococci
are the second most common cause of nosocomial infections and 35.5% of hospital-associated
enterococcal infections are vancomycin resistant [4]. Recent US hospitals surveillance studies
show that approximately 80% of E. faecium clinical isolates during 2011 to 2014 were resistant
to vancomycin (http://gis.cdc.gov/grasp/PSA/MapView.html). Moreover, infections with
VREfm, compared to vancomycin-susceptible enterococci (VSE), are associated with
increased morbidity, mortality, healthcare costs, and duration of hospital stay [5]. Therefore,
VREfm has been listed by the US Centers for Disease Control and Prevention (CDC) as a tar-
get multidrug-resistant organism that requires improved infection control practice and infec-
tion reduction measures for both acute and long-term healthcare facilities [6]. Current
antibiotic treatment of VREfm infections include linezolid, daptomycin, and tigecycline [7, 8].
Of these, daptomycin has potent bactericidal activity against enterococci, low risk of serious
side-effects, and minimal drug-drug interactions. Daptomycin has been increasingly used in
the US and other countries to treat serious staphylococcal and enterococcal infections, includ-
ing infections caused by VREfm [1, 9–11]
Resistance to daptomycin is a serious clinical problem for treatment of severe VREfm infec-
tions, although it is still uncommon among clinical isolates worldwide [12, 13]. The mecha-
nisms of daptomycin resistance in VREfm isolates remains to be fully elucidated. Daptomycin
inserts into the plasma membrane in a calcium-dependent manner and subsequently disrupts
the functional integrity of the cell membrane. Genomic sequencing analyses have revealed an
association between daptomycin resistance and mutations in genes encoding the LiaFSR
three-component regulatory cell envelope stress response pathway [14–20] and phospholipid
biosynthesis enzymes cardiolipin synthase (Cls) in enterococci [14, 19, 21, 22]. It has been
reported that mutations in the LiaFSR result in reduced binding of daptomycin to the cell sur-
face in E. faecium [15, 17], and eventually lead to failures during daptomycin therapy with a
subsequent mutation, most commonly in the cls gene [19, 20]. Among the mutations identi-
fied, substitutions in LiaR (W73C), LiaS (T120A) and Cls (H215R and R218Q) are among the
most frequently observed [15, 20, 22], although mutations in either gene alone are not suffi-
cient to confer a resistant phenotype in enterococci [16, 19, 21].
The VRE population in hospitals is highly diverse [1, 23, 24]. It is of interest for patient
management and infection control to understand the antimicrobial resistance profiles, molec-
ular epidemiology and transmission of local VRE populations in healthcare settings. However,
current data on the clonal and temporal evolution of VRE clinical isolates in the US hospitals
are limited. Westchester Medical Center (WMC) is a 652-bed tertiary-care medical center in
the lower Hudson Valley of suburban New York City. VRE was first identified at WMC in
May 1991 and an outbreak of VRE bloodstream infections in oncology patients was reported
the same year [25]. Subsequent surveillance cultures for VREs in 1993–1995, 2009 and 2013
confirmed high rates of colonization (15–40%) among inpatients [26] (Wang et al., unpub-
lished data). Recently, we identified a novel clone ST736 that accounts for 76.6% of daptomy-
cin-nonsusceptible E. faecium isolates at our institution [27]. Since then, ST736 strains have
been expanding to other hospitals in New York [28, 29], Washington [29, 30], Texas [15, 31],
Maryland (https://pubmlst.org/efaecium/), Canada [32], countries in South America [15] and
Caribbean [33], as well as Germany [34]. Moreover and the most worrisome, ST736 has been
reported as the most common VREfm strains on hospital environmental surfaces and in
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laundry facility of some US teaching hospitals [31, 35]. The objectives of this study were to
assess the evolution in clonality and antimicrobial susceptibility profiles of local VREfm popu-
lations, to explore the potential role of genomic mutations and nosocomial transmission in the
emergence and spread of daptomycin-nonsusceptible ST736 strains.
Materials and methods
Enterococcus faecium clinical isolates
A total of 250 E. faecium clinical isolates, including 239 VREfm and 11 vancomycin-susceptible
E. faecium (VSEfm) isolates, were included in this study. All isolates were recovered from
patients with an infection, with the exception of one from an environmental sample, in a ter-
tiary-care medical center of suburban New York City. Isolates were collected from three differ-
ent study periods: 1) 1994–1995 (n = 43): Forty-nine VRE isolates were randomly selected
from a collection of saved isolates during an outbreak investigation from July 1994 through
July 1995. Of these, 43 E. faecium-VRE isolates were included, while 6 E. faecalis-VRE isolates
were excluded in the analysis; 2) 2013 (n = 92): this included all non-duplicate, consecutive
VREfm isolates recovered from January through October 2013; and 3) 2009–2012 (n = 115):
which comprised all confirmed daptomycin-nonsusceptible E. faecium (DNSEfm) isolates and
representing daptomycin-susceptible isolates spanning different months of each year. One E.
faecium isolate per patient was chosen unless there were two isolates from the same patient
with different sequence types (ST) or with different susceptibility (susceptible vs. nonsuscepti-
ble) to daptomycin. All enterococci isolates were identified by conventional biochemical tests
and confirmed using the MALDI Biotyper CA system (Bruker, Billerica, MA) and/or DNA
sequencing analysis of 16S rRNA gene. Antimicrobial susceptibilities of E. faecium isolates
were measured by broth microdilution with the MicroScan 96Plus test system and daptomy-
cin-nonsusceptibility (MIC > 4 μg/mL) was confirmed by E-test as described previously [27].
Next-generation sequencing (NGS) and data analysis
DNA extraction, quantitation and library preparation were carried out as described previously
[27]. Paired-end sequencing was performed using either Illumina MiSeq (2×250 bp) at New
York Medical College (Valhalla, NY) or HiSeq 2000 (2×100 bp) at the Cold Spring Harbor
Laboratory (Cold Spring Harbor, NY). Illumina raw sequencing reads were trimmed to clip
adapters and low-quality bases (Phred score <10) using Trimmomatic v0.36 [36]. The
trimmed reads were examined for both sample swapping and taxonomic abundance using
Kraken v0.10.5-beta [37] and assembled de novo with MEGAHIT v1.1.2 [38]. From the assem-
blies, the multilocus sequence typing (MLST)-based clonality was determined in silico using
BLAST-based tool (https://github.com/tseemann/mlst) and the PubMLST database (https://
pubmlst.org/) [39]. Sanger DNA sequencing was used for allele confirmation in some isolates
when NGS failed to retrieve MLST or new alleles were found. Trimmed sequencing reads were
also aligned to the reference genome of a local E. faecium ST736 strain E39 (RefSeq accession
number NZ_CP011281.1) to produce a reference-based whole-genome alignment including
single nucleotide variant (SNV) and indels (insertions and/or deletions) with Snippy v3.1
(https://github.com/tseemann/snippy).
Bayesian phylogenetic analyses
To investigate the phylogenetic relationship and the divergence time of E. faecium circulating
at local patient population, Bayesian Evolutionary Analysis by Sampling Trees 2 (BEAST 2)
v2.4.7 [40] was used to jointly estimate molecular clock phylogeny, rate of evolution,
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divergence times and other evolutionary parameters. By using Snippy, a reference-based
whole-genome alignment was generated to include all 250 E. faecium samples. To reduce
excessive computational load, three isolates with low depth of genomic coverage were
excluded, which resulted a final of 247 samples and 487,932 sites (479,196 invariant sites) for
the BEAST analysis.
Bayesian Markov Chain Monte Carlo (MCMC) analysis was performed using the Hasegawa-
Kishino-Yano (HKY) [41] nucleotide substitution model, along with a coalescent constant pop-
ulation tree prior and a discrete gamma-distributed among-site-rate-variation model with four
categories [42]. A strict molecular clock model was employed, and tip dates were set from the
sample collection dates. The MCMC chain was run for 1.5 billion states and sampled every
100,000 states. 10% sampled states were discarded as burn-in. Convergence was assessed using
Tracer v1.7 [43], and effective sample size (ESS) values above 200 were accepted. A maximum
clade credibility (MCC) tree was summarized with TreeAnnotator (available in the BEAST 2
v2.4.7 package) and visualized in Figtree v1.4.4 (http://tree.bio.ed.ac.uk/software/figtree/).
Mutation analysis of liaFSR and cls genes
The assembled genome of each isolate with reference to the E. faecium strain E39 (ST736,
accession numbers CP011281-CP011285, CP015123) was blasted against the liaS (1,069 bp)
and the liaR (634 bp) gene sequences of strain DO (ST18, accession no. CP003583), and the cls
(1,452 bp) gene sequence of strain UW7606x64/3 TC1 (ST192, accession no. CP013009). Cor-
responding gene sequences for each isolate were extracted. SNPs of liaFSR and cls genes in all
E. faecium isolates and genetic alterations between isolates of each isogenic pair were called
out using SNP-sites (http://dx.doi.org/10.1099/mgen.0.000056), in association with daptomy-
cin resistance from the CARD database (https://card.mcmaster.ca/).
Statistical analysis
The Fisher’s exact test from the GraphPad Prism software (version 7.0) was used to determine
the statistical significance of association between the different STs of E. faecium with distinct
clinical and microbiological characteristics.
Accession numbers
The complete genomes of four representative ST736 strains (E39, E232, E243, and E240) were
deposited to GenBank with accession numbers of CP011281-CP011285, CP015123, and
CP017787 to CP017801. The untrimmed Illumina raw sequencing reads for all 250 E. faecium
isolates were uploaded to GenBank under BioProject PRJNA386994.
Results
Clonality of VREfm population from 1994–1995 vs. 2013
To determine the population dynamics and evolution of VREfm clinical isolates and correla-
tion between distinct clones and daptomycin susceptibility, we determined the sequence types
(ST) of 92 non-duplicated, consecutive VREfm isolates from 86 inpatients hospitalized during
January through October 2013. Two of these patients carried VREfm isolates with different
STs (ST412 and ST736), while four patients had VREfm isolates with one isolate susceptible
and another nonsusceptible to daptomycin. Eight distinct STs with three dominant clones
(ST736, ST18 and ST412) were recognized among the 2013 VREfm clinical isolates. Of these,
43 (46.7%) isolates belonged to ST736, followed by ST18 (n = 24, 26.1%), ST412 (n = 19,
20.7%) and five other STs each with one to two isolates (Table A in S1 File).
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For comparison, we also analyzed 43 VREfm isolates randomly selected from patients in
1994–1995, the earliest collection of VREfm isolates available for this study. ST736 was not
detected in these VREfm isolates. By contrast, 33 of 43 (76.7%) VREfm isolates from 1994–
1995 were ST17, a prototype of E. faecium clonal complex 17 (CC17) or clade A1 (Fig 1). Addi-
tional clones detected among the 1994–1995 VREfm isolates included ST18 (n = 3, 7.0%),
ST16 (n = 2, 4.7%) ST535 (n = 2, 4.7%), and three other STs (ST20, ST186 and ST280) with
one isolate each.
In addition, the clonality of 115 E. faecium isolates from 2009 to 2012 were examined. ST736
strains were detected in all years between 2009 and 2012. The number of E. faecium isolates
from different study years and distribution in clonality are summarized in Table A in S1 File.
Antimicrobial susceptibility profiles of VREfm from 1994–1995 vs. 2013
The antimicrobial susceptibility profiles of VREfm isolates from 1994–1995 and 2013 are
shown in Table 1. A significant change in antimicrobial resistance profiles was observed
between VREfm isolates from 1994–1995 and from 2013. All 43 VREfm isolates from 1994–
1995 were susceptible to linezolid and daptomycin. By contrast, one of 92 (1.1%) VREfm iso-
lates from 2013 were resistant to linezolid (p> 0.05) and 26 (28.3%) isolates from 2013, includ-
ing 20 ST736 and 6 non-ST736 strains, were resistant to daptomycin (p< 0.0001). A point
mutation G2576T of the 23S rRNA [44] was confirmed in the linezolid-resistant VREfm isolate
(E243) from 2013. In addition, the 2013 VREfm isolates showed higher resistance rate to tetra-
cycline than those from 1994–1995 (90.2% vs. 32.6%, p< 0.0001). Of 14 tetracycline-resistant
VREfm isolates from 1994–1995, 13 isolates carried tet(M) resistance gene and one isolate pos-
sessed tet(L) gene. The number of VREfm isolates carrying both tet(M) and tet(L) was
increased significantly from 14.3% (2 of 14) in 1994–1995 to 43.4% (36 of 83) in 2013
(p< 0.01). All VREfm isolates from 1994–1995 and 2013 carried the vanA gene with an excep-
tion of one ST186 isolate (E508) from 1995, in which a vanB gene was detected.
Evolutional analysis on the emergence of VREfm ST736 clone
To explore the evolution of VREfm and estimate the possible emergence time of VREfm
ST736 at our institution, we selected E. faecium isolates with a minimum breadth coverage of
Fig 1. Clonality of VREfm from 1994–1995, 2009–2012 and 2013. The sequence types (STs) of VREfm were derived from whole-genome sequences as described in the
text. Refer to Table A in S1 File for more information on clonal distribution of E. faecium clinical isolates (1994–2013).
https://doi.org/10.1371/journal.pone.0209785.g001
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>60% reference genome, and performed the Bayesian evolutionary analysis. The final analysis
included 487,932 sites (479,196 invariant sites) from the whole-genome alignment of 247 E.
faecium isolates. As shown in Fig 2, BEAST analysis suggested that VREfm ST736 strains
might have emerged between 1996 and 2009, most likely between 2004 and 2006 at our institu-
tion based on BEAST analysis. In addition, multiple subclusters were observed in the major
branch of ST736 groups, each with one or more closely related isolates.
Association between distinct VREfm clones and daptomycin susceptibility
To further our understanding [27] on the association between different VREfm clones and
daptomycin nonsusceptibility, we analyzed 92 VREfm isolates representing an unbiased collec-
tion of all hospitalized patients with VREfm infections from January through October 2013.
Interestingly, clone ST736 strains accounted for only 46.7% (43 of 92) of all VREfm isolates
examined in 2013 but 76.9% (20 of 26) of DNSEfm from this study period (p = 0.0002). The
prevalence of ST736 as DNSEfm (46.5%, 20 of 43) was significantly higher than that of non-
ST736 VREfm isolates from the same study period (6 of 49, 12.2%, p< 0.001). The distribution
of daptomycin MICs of different E. faecium clones were shown in Fig 3 and Tables B and C in
S1 File. The daptomycin MIC90 of ST736 strains was 32 μg/mL, which was significantly higher
than those from other non-ST736 strains (MIC90: 8 μg/mL, p<0.01).
Mutations in liaFSR and cls and daptomycin resistance
The mutations and frequency of liaFSR and cls reported to be associated with daptomycin
resistance in E. faecium [45] were analyzed and compared between ST736 and non-ST736 iso-
lates (Table 2). Two mutations in liaFSR (W73C and T120A) and several mutations in cls
(N13I, N13T, A20D, H215R, R218Q) were detected, while the remaining mutations described
by Arias et al. [14] and listed in the CARD database were not seen in our isolates. Strikingly, all
ST736 isolates (n = 111, 100%) examined had co-mutations (W73C and T120A) in the liaFSR,
which was significantly higher than that detected in non-ST736 isolates (17 of 139, 12.2%,
p< 0.0001).
The overall prevalence of mutations (N13I, N13S, N13T, A20D, H215R, R218Q) in cls was
6.8% (17 of 250), which was much higher in ST736 (11.7%, 13 of 111) than in non-ST736 iso-
lates (2.9%, 4 of 139, p = 0.0041, Table 2). Significantly higher prevalence of mutation in cls
was also noticed in DNSEfm (30.2%, 16 of 53) than in DSEfm isolates (0.5%, 1 of 197, p
<0.0001).
Thirty-eight of 111 (34.2%) ST736 isolates with liaFSR mutations were resistant to dapto-
mycin, while all 13 ST736 isolates with both liaFSR and cls mutations exhibited a daptomycin-
Table 1. Antimicrobial resistance profiles of vancomycin-resistant E. faecium (VREfm) clinical isolates, 1994–
1995 (n = 43) versus 2013 (n = 92)a.





Ampicillin 41 (95.3) 92 (100) 0.0998
Daptomycin 0 26 (28.3) <0.0001
Linezolid 0 1 (1.1) 1.0000
Tetracycline 14 (32.6) 83 (90.2) <0.0001
Vancomycin 43 (100) 92 (100) 1.0000
a All VREfm isolates from 1994–1995 and 2013 were resistant to erythromycin and levofloxacin. The data shown in
the parenthesis are percent of isolates with resistance to specific antibiotics.
https://doi.org/10.1371/journal.pone.0209785.t001
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resistant phenotype. Moreover, ST736 isolates with cls mutations (n = 13) appeared to confer
high resistance to daptomycin (MIC50 of 32 μg/mL), compared to those without cls mutations
(MIC50: 8 μg/mL) (Table 3 and Table B in S1 File).
Thirty of 111 (27.0%) VREfm ST736 isolates had prior exposure to daptomycin within 12
months before their recovery from patients. VREfm ST736 isolates from patients with prior
daptomycin exposure were more likely to be resistant to daptomycin (20/30, 66.7%) than those
without prior exposure (18 of 81, 22.2%, p < 0.0001) with a relative risk of 3.0 (95% confident
interval: 1.85–4.84). Moreover, 10 of 13 ST736 isolates with cls mutations had prior use of dap-
tomycin. As shown in Table 4, four of six patients with isogenic pair of ST736 isolates devel-
oped resistance during daptomycin therapy by inducing cls mutations.
Fig 2. Evolutional analysis on the emergence of VREfm ST736 strains. (A) Maximum clade credibility (MCC) tree inferred using BEAST 2 with a whole-genome-based
alignment that includes 247 E. faecium isolates and 487,932 sites. Bayesian analysis was run using a strict molecular clock model and with an HKY+G nucleotide
substitution model assuming a coalescent constant population tree prior. Numbers above branches indicate posterior probabilities. (B) A zoomed-in version of the whole
MCC tree showing the ST736 clade and the estimated divergence time of each node in year.
https://doi.org/10.1371/journal.pone.0209785.g002
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Two VREfm ST736 isolates (E243 and E253) had a daptomycin MIC of>256 μg/mL. Com-
parative genomic analysis of isogenic pair revealed no mutations in the chromosome of E243.
For isolate E253, mutations in the cls (A20D) and a tyrosine kinase (P90H) as well as frameshift
in a gene coding the TlyA family rRNA (cytidine-2’-O)-methyltransferase were also identified
Fig 3. Distribution of daptomycin MIC among different sequence type (ST) of E. faecium strains from 1994 to 2013.
The cumulated numbers of E. faecium strains included in this analysis were ST17 (n = 3), ST18 (n = 38), ST412 (n = 35),
ST736 (n = 111) and miscellaneous (n = 33). The square box symbol represents the daptomycin MIC90 of each ST strains.
Refer to Table C in S1 File for distribution of daptomycin MIC of major E. faecium clones for each time period of
evaluation.
https://doi.org/10.1371/journal.pone.0209785.g003
Table 2. Frequency of the liaRS and cls mutations among daptomycin-nonsusceptible and daptomycin-susceptible E. faecium clinical isolatesa.
liaRS mutations cls mutations
E. faecium ST group No. of isolates No. % p valueb No. % p value
DNSEfm ST736 38 38 100.0 <0.0001 13 34.2 0.5076
Non-ST736 15 4 26.7 3 20.0
All STs 53 45 84.9 Footnotec 16 30.2 Footnoted
DSEfm ST736 73 73 100.0 <0.0001 0 0 >0.05
Non-ST736 124 13 10.5 1 0.8
All STs 205 107 52.2 1 0.5
Total ST736 111 111 100.0 <0.0001 13 11.7 0.0041
Non-ST736 139 17 12.2 4 2.9
All STs 250 128 51.2 17 6.8
a DNSEfm: Daptomycin-nonsusceptible E. faecium; DSEfm: Daptomycin-susceptible E. faecium
b The p value between ST736 and non-ST736 isolates.
c p< 0.001 between DNSEfm (84.9%) and DSEfm (52.2%) isolates.
d p< 0.001 between DNSEfm (30.2%) and DSEfm (0.5%) isolates.
https://doi.org/10.1371/journal.pone.0209785.t002
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on the chromosome (Table 5). In addition, mutations in different insertion sequence (IS) fam-
ily transposases were noticed in the plasmids of both isolates.
Nosocomial transmission of VREfm ST736
To assess potential nosocomial transmission in spreading DNSEfm, a phylogenetic tree with
ST736 isolates from 2013 was constructed (Fig 4A). Notably, 31 of 37 ST736 VREfm isolates
Table 3. Common mutations and frequency of the liaFSR and cardiolipin synthase (cls) genes detected among daptomycin-nonsusceptible VREfm clinical isolates.
E. faecium clone(s) No. of isolates Gene(s) Mutation No. of isolates with mutation (%) Daptomycin MIC range (μg/mL)
ST736 38 liaFSR liaR.W73C 38 (100) 6 - >256
liaFSR liaS.T120A 38 (100) 6 - >256
cls N13I (A38T) 1 (2.6) 32
cls N13S (A38G) 1 (2.6) 32
cls N13T (A38C) 6 (15.8%) 16–96
cls A20D 1 (2.6) >256
cls H215R 3 (7.9) 8–16
cls R218Q 1 (2.6) 8
Non-ST736 15 liaFSR liaR.W73C 4 (26.7) 6–16
liaFSR liaS.T120A 4 (26.7) 6–16
cls N13S 1 (6.7) 16
cls H215R 1 (6.7) 12
cls R218Q 1 (6.7) 16
https://doi.org/10.1371/journal.pone.0209785.t003
Table 4. Daptomycin exposure and development of resistance during therapy in patients with isogenic pairs of ST736 strains.
Year Patient ST736
isolate






liaFSR mutation(s) cls mutation
(s)
2010 107 E51 Blood - 4 liaR.W73C, liaS.
T120A
-
E53 Wound 36 + 64 liaR.W73C, liaS.
T120A
N13I
2011 74 E148 Blood + 2 liaR.W73C, liaS.
T120A
E91 Blood 9 + 64 liaR.W73C, liaS.
T120A
N13I
124 E145 Blood + 2 liaR.W73C, liaS.
T120A
E146 Urine 26 + 32 liaR.W73C, liaS.
T120A
N13I




44 + >256 liaR.W73C, liaS.
T120A
184 E352 Wound - 2 liaR.W73C, liaS.
T120A
E242 Wound 4 + 8 liaR.W73C, liaS.
T120A
185 E300 Wound - 3 liaR.W73C, liaS.
T120A
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analyzed fell into a closely related cluster with less than 50 SNVs among different isolates. Of
these, 8 VREfm isolates from 6 patients revealed a distinct subcluster with less than 10 SNVs (0–
9 SNVs). As shown in Fig 4, both epidemiological links (e.g., patients staying in the same hospi-
tal bed/room, visiting the same clinic on the same day, or hospitalized during the same period
with at least two weeks of overlap) and SNVs-based genomic evidence were identified among
the 6 patients in this subcluster, supporting the occurrence of nosocomial transmission [46].
Discussion
In this study, we sought to determine if ST736 had long been in existence or only recently
emerged at our institution. Comparative genomic analysis of clinical isolates revealed a dra-
matic change in the clonality and antimicrobial resistance profiles of local E. faecium popula-
tion from 1994–1995 to 2013. The dominant clone of VREfm isolates in 1994–1995 was ST17
(77%), a prototype strain of CC17 or clade A1, when VREfm started emerging in the mid-1990
in the US [47]. No ST736 clones were identified among VREfm isolates from 1994–1995. By
contrast, ST736 strains became predominant, accounting for 46.7% of local VREfm isolates in
2013. E. faecium ST18 appeared to be only clone continuously detectable in both study periods
(1994–1995 and 2013). VREfm ST736 continues to be the dominant clone among isolates of
2014 (37.7%) and 2015 (36.9%) examined (data not shown). Bayesian evolutionary analysis,
with additional E. faecium isolates from 2009 to 2012, provided evidence for the recent emer-
gence of VREfm clone ST736 between 1996 and 2009. Based on the BEAST analysis, ST736
strains most likely emerged between 2004 and 2006. Due to the lack of VREfm isolates saved
between 1996 and 2008, it would be difficult to determine the precise year of ST736
emergence.
In this population-based study, non-duplicate VREfm isolates from all patients admitted
during January to October 2013 were analyzed. This eliminated potential bias in selecting iso-
lates. In 2013, ST736 strains accounted for only 46.7% (43/92) of all VREfm but 76.9% (20/26)
of daptomycin-resistant VREfm isolates. This confirms that the observed high occurrence of
DNSEfm in clone ST736 strains is not simply due to its high prevalence at our institution [27].
In 2013, 20 of 43 (46.5%) ST736 isolates were DNSEfm, while only 6 of 49 (12.2%) non-ST736
isolates were DNSEfm (p<0.0001). The probability of an ST736 isolate to be daptomycin-non-
susceptible is significantly higher than that of a non-ST736 isolate (p = 0.0002) with an esti-
mated relative risk of 3.9 (95% confidence interval: 1.7 to 8.9). Our data highlight the risk of





Genome Positiona Locus tag (E39) Mutation/amino acid
change
Predicted function
E243 >256 NZ_CP011281 Chromosome No mutations detected
NZ_CP011282 Plasmid-1 136763 XM37_RS14230 c.758_759delTGinsCC
p.Leu253Ser
IS982 family transposase
E253 >256 NZ_CP011281 Chromosome 792300 XM37_RS03700 c.698dupG p.Glu234fs TlyA family rRNA (cytidine-2’-O)-
methyltransferase
1033952 XM37_RS05010 c.59C>A p.Ala20Asp Cardiolipin synthase
1842891 XM37_RS08900 c.269C>A p.Pro90His Tyrosine kinase
NZ_CP011282 Plasmid-1 17787 XM37_RS13585 c.819A>C p.Glu273Asp IS30 family transposase
79592 XM37_RS13930 c.116G>A p.Gly39Asp IS6 family transposase IS1216E
93719 XM37_RS14010 c.67C>T p.Pro23Ser Transposase
147157 XM37_RS14285 c.56A>G p.Asp19Gly IS6 family transposase
a Position numbers corresponded to the nucleotide no. of isolate E39.
https://doi.org/10.1371/journal.pone.0209785.t005
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ST736 clone in dissemination of daptomycin resistance and challenge in management of
patients infected with ST736 VREfm strains.
The mechanisms of resistance to daptomycin appear to be diverse for VREfm strains with
different genetic backgrounds [10, 45, 48]. Both de novo and developed resistance during dap-
tomycin therapy have been reported [10]. Among several genomic pathways proposed, a hier-
archical adaption via sequential mutations in the liaFSR signaling system and cls appears to be
the most common mechanism associated with daptomycin resistance identified in enterococci
[15, 16, 19, 49–51]. Since most of published data are based on analysis of a limited number of
clinical isolates and/or laboratory-derived mutants, our current report represents the largest
collection of E. faecium clinical isolates that can serve as an independent validation on the
Fig 4. Possible nosocomial transmission of ST736 VREfm isolates among inpatients. (A). Chromosomal SNVs-based phylogenetic tree of representing VREfm ST736
isolates from 2013 (n = 37). Tree was constructed using the neighbor-joining method. (�): VREfm E39 was used as reference isolate. The two non-ST736 isolates were used
as out of group control. (B) Possible transmission route for a selected group of 6 patients with 8 closely related E. faecium isolates. Solid arrow: transmission with
epidemiological evidence [i.e., stayed in the emergency room (PT161 and PT182), on the same bed (PT161 and PT127), in the same medical intensive care unit (PT182
and PT184), or hospitalized during the same time period with overlap for at least 2 weeks (PT127 and PT191, PT161 and PT177)]; dashed arrow: patients had no direct
epidemiological links. All transmissions with the exception between patients PT161 and 127 were suggested by SNVs-based minimum spanning tree [46]; Next to each
arrow between two samples is the number of SNV differences between the samples. (C) SNVs identified based on whole-genome sequencing with clinical data of the
patients. Sequences identical to those from isolate E232 were shown in dot (.); SNVs were listed and shadowed in gray.
https://doi.org/10.1371/journal.pone.0209785.g004
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correlation between some previously described mutations and daptomycin resistance. Strik-
ingly, we found that all ST736 VREfm isolates (n = 111) carried the two common mutations
(W73C and T120A) in the liaFSR system. Such a high mutation rate in the liaFSR system
among ST736 strains has not yet been documented in any E. faecium with other genetic back-
ground. Mutations in liaFSR have been associated with high daptomycin MICs [16, 20] and
failure in treatment of bacteremia caused by daptomycin-susceptible VREfm [52, 53]. Our
findings and data from other studies may serve as the basis of a potential diagnostic tool to
screen and identify isolates carrying mutations in the liaFSR system, and/or isolates with a spe-
cific genotype (i.e., ST736) that may predispose to subsequent development of in vivo dapto-
mycin resistance, thus to optimize the use of daptomycin against enterococci in clinical
settings. Also, it would be worthy to investigate if relatively poor response to daptomycin ther-
apy in patients infected with ST736 strains, as compared to those infected with non-ST736
VREfm strains.
The estimated emergence of ST736 strains in the mid-2000s at our institution seems coinci-
dent with the initial clinical use of daptomycin after FDA’s approval in 2003. It is unclear if the
co-mutation (W73C and T120A) of the liaFSR in ST736 strains resulted from a serial of evolu-
tional events and/or positive selections by daptomycin, and if this genetic alteration indeed
contributed to its rapid expansion and dissemination at our institution with a relatively high
usage of daptomycin.
Mutations in either liaFSR or cls alone may not be sufficient in conferring phenotypic resis-
tance to daptomycin in enterococci [21, 45]. In our study, only about one-third (38/111,
34.2%) of ST736 strains carrying the two mutations in liaFSR exhibited daptomycin-resistant
phenotype (MIC > 4 μg/mL). Also, one VREfm isolate (non-ST736) harboring cls mutations
was susceptible to daptomycin. Nevertheless, in an E. faecium clone like ST736 with all strains
harboring a predisposing genetic alteration in the liaFSR, subsequent mutation in the cls gene
seems to be sufficient to confer daptomycin resistance. This is based on our observation that
all 13 VREfm ST736 isolates with mutations in both liaFSR and cls exhibit daptomycin-resis-
tant phenotype. It is noteworthy that the most common cls mutation among ST736 strains is
an asparagine to threonine (N13T) substitution, differing from those (N13I and N13S)
reported in enterococci with other genetic background [14, 21, 22, 45]. The N13T substitution
of cls was previously described as N12T in one California E. faecium isolate with high-level
daptomycin resistance (MIC of>256 μg/mL) [54]. Moreover, the thirteen ST736 isolates car-
rying mutations in both liaFSR and cls displayed a daptomycin MIC50 of 32 μg/mL (ranging
from 8 to>256 μg/mL), which is much higher than that of daptomycin-resistant ST736 iso-
lates without cls mutations (MIC50 of 8 μg/mL), indicating that co-mutations in both liaFSR
and cls might have predisposed to high daptomycin MICs in ST736 strains. On the other hand,
25 of 38 (65.8%) ST736 DNSEfm strains did not carry cls mutations, suggesting diverse mecha-
nisms of resistance to daptomycin in E. faecium [45] and a necessity of further exploring other
alternative genomic pathways associated with daptomycin resistance. Notably, VREfm isolate
E253 had a daptomycin MIC of>256 μg/mL. In addition to a mutation in the cls (A20D), two
new genetic alterations, including mutation in a tyrosine kinase (P90H) and a frameshift in a
gene coding the TlyA family rRNA (cytidine-2’-O)-methyltransferase, were also identified on
the chromosome of this isolate, as well as mutations in insertion sequence (IS) family transpo-
sases on the plasmid. Previously, mutation in histidine kinase has been reported in a daptomy-
cin-resistant E. faecium isolate [19]. Given the important role of protein kinases in regulating
bacterial physiology and stress response [55], it would be interesting to determine if bacterial
kinases, including tyrosine kinase described in this study, are associated with daptomycin
resistance in enterococci. There was no significant genetic alteration in an isogenic pair of
VREfm isolates with different daptomycin MICs (4 μg/mL for E232 and>256 μg/mL for
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E243), highlighting the complexity and other potential mechanisms such as small RNA [48]
and/or differential gene expression that may have involved in daptomycin resistance.
The observed high occurrence of DNSEfm at our institution likely resulted from the unique
genetic characteristics of ST736 strains that predispose to daptomycin resistance and nosoco-
mial dissemination of DNSEfm. Previously, we reported that 81.7% (17 of 21) DNSEfm from
2009 to 2012 had a prior exposure to daptomycin [27]. In this study, we noticed that the major-
ity (76.9%, 10 of 13) of DNSEfm isolates with cls muations were from patients with prior expo-
sure to daptomycin while hospitalized during 2009 to 2012. The high prevalence of ST736
strains harboring a predisposing mutation in the liaFRS system seems to increase the likeli-
hood of developing resistance by either introducing or selecting mutation in the cls during
daptomycin therapy. Only 6 of 20 (30%) patients with DNSEfm in 2013 had prior exposure to
daptomycin. Nosocomial transmission might have occurred and attributed to the observed
high prevalence of DNSEfm in 2013 in spite of the implementation of hospital-wide enhanced
infection control measures, including the use of ultraviolet environmental disinfection in
patient rooms [56].
The limitations of this study include: 1) all VREfm isolates examined were from a single
institution; 2) the lack of VREfm isolates between 1996 and 2008 for a more precisely evolu-
tional analysis; and 3) we only examined mutations in liaFSR and cls that are known to be asso-
ciated with daptomycin resistance in E. faecium. Other mutations and additional daptomycin
resistance mechanisms are under further investigation.
In conclusion, our study demonstrates an evolutionary change in clonality and antimicrobial
susceptibility of E. faecium population over the past 20 years and a recent emergence of VREfm
clone ST736 associated with daptomycin nonsusceptibility at our institution. For clone ST736
strains, resistance to daptomycin likely resulted from predisposing genetic alterations in the
liaFSR, totaling by mutations in the cls and possibly other genes and pathways, through evolu-
tion and/or sequential adaption. The high occurrence of ST736 strains with increased risk of
developing daptomycin resistance during therapy and nosocomial dissemination of VREfm
[57] might have contributed to the observed high prevalence of DNSEfm at our institution.
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